Cargando…
Characterization of erythroferrone oligomerization and its impact on BMP antagonism
Hepcidin, a peptide hormone that negatively regulates iron metabolism, is expressed by bone morphogenetic protein (BMP) signaling. Erythroferrone (ERFE) is an extracellular protein that binds and inhibits BMP ligands, thus positively regulating iron import by indirectly suppressing hepcidin. This al...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491252/ https://www.ncbi.nlm.nih.gov/pubmed/37693455 http://dx.doi.org/10.1101/2023.09.01.555965 |
_version_ | 1785104022211919872 |
---|---|
author | Mast, Jacob F Leach, Edmund A E Thompson, Thomas B |
author_facet | Mast, Jacob F Leach, Edmund A E Thompson, Thomas B |
author_sort | Mast, Jacob F |
collection | PubMed |
description | Hepcidin, a peptide hormone that negatively regulates iron metabolism, is expressed by bone morphogenetic protein (BMP) signaling. Erythroferrone (ERFE) is an extracellular protein that binds and inhibits BMP ligands, thus positively regulating iron import by indirectly suppressing hepcidin. This allows for rapid erythrocyte regeneration after blood loss. ERFE belongs to the C1Q/TNF related protein (CTRP) family and is suggested to adopt multiple oligomeric forms: a trimer, a hexamer, and a high molecular weight species. The molecular basis for how ERFE binds BMP ligands and how the different oligomeric states impact BMP inhibition are poorly understood. In this study, we demonstrated that ERFE activity is dependent on the presence of stable dimeric or trimeric ERFE, and that larger species are dispensable for BMP inhibition. Additionally, we used an in-silico approach to identify a helix, termed the ligand binding domain (LBD), that was predicted to bind BMPs and occlude the type I receptor pocket. We provide evidence that the LBD is crucial for activity through luciferase assays and surface plasmon resonance (SPR) analysis. Our findings provide new insight into how ERFE oligomerization impacts BMP inhibition, while identifying critical molecular features of ERFE essential for binding BMP ligands. |
format | Online Article Text |
id | pubmed-10491252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-104912522023-09-09 Characterization of erythroferrone oligomerization and its impact on BMP antagonism Mast, Jacob F Leach, Edmund A E Thompson, Thomas B bioRxiv Article Hepcidin, a peptide hormone that negatively regulates iron metabolism, is expressed by bone morphogenetic protein (BMP) signaling. Erythroferrone (ERFE) is an extracellular protein that binds and inhibits BMP ligands, thus positively regulating iron import by indirectly suppressing hepcidin. This allows for rapid erythrocyte regeneration after blood loss. ERFE belongs to the C1Q/TNF related protein (CTRP) family and is suggested to adopt multiple oligomeric forms: a trimer, a hexamer, and a high molecular weight species. The molecular basis for how ERFE binds BMP ligands and how the different oligomeric states impact BMP inhibition are poorly understood. In this study, we demonstrated that ERFE activity is dependent on the presence of stable dimeric or trimeric ERFE, and that larger species are dispensable for BMP inhibition. Additionally, we used an in-silico approach to identify a helix, termed the ligand binding domain (LBD), that was predicted to bind BMPs and occlude the type I receptor pocket. We provide evidence that the LBD is crucial for activity through luciferase assays and surface plasmon resonance (SPR) analysis. Our findings provide new insight into how ERFE oligomerization impacts BMP inhibition, while identifying critical molecular features of ERFE essential for binding BMP ligands. Cold Spring Harbor Laboratory 2023-09-02 /pmc/articles/PMC10491252/ /pubmed/37693455 http://dx.doi.org/10.1101/2023.09.01.555965 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Mast, Jacob F Leach, Edmund A E Thompson, Thomas B Characterization of erythroferrone oligomerization and its impact on BMP antagonism |
title | Characterization of erythroferrone oligomerization and its impact on BMP antagonism |
title_full | Characterization of erythroferrone oligomerization and its impact on BMP antagonism |
title_fullStr | Characterization of erythroferrone oligomerization and its impact on BMP antagonism |
title_full_unstemmed | Characterization of erythroferrone oligomerization and its impact on BMP antagonism |
title_short | Characterization of erythroferrone oligomerization and its impact on BMP antagonism |
title_sort | characterization of erythroferrone oligomerization and its impact on bmp antagonism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491252/ https://www.ncbi.nlm.nih.gov/pubmed/37693455 http://dx.doi.org/10.1101/2023.09.01.555965 |
work_keys_str_mv | AT mastjacobf characterizationoferythroferroneoligomerizationanditsimpactonbmpantagonism AT leachedmundae characterizationoferythroferroneoligomerizationanditsimpactonbmpantagonism AT thompsonthomasb characterizationoferythroferroneoligomerizationanditsimpactonbmpantagonism |